High-sensitive LC-MS/MS method for the simultaneous determination of mirodenafil and its major metabolite, SK-3541, in human plasma: application to microdose clinical trials of mirodenafil.

A high-sensitivity LC/MS/MS method was developed and validated for the simultaneous determination of mirodenafil and its major metabolite, SK-3541, in human plasma. Mirodenafil, SK-3541, and udenafil as an internal standard were extracted from plasma samples with methyl tert-butyl ether. Chromatographic separation was performed on a Luna phenyl-hexyl column (100 × 2.0 mm) with an isocratic mobile phase consisting of 5 mM ammonium formate and ACN (23:77, v/v) at a flow rate of 0.35 mL/min. Detection and quantification were performed using a mass spectrometer in selected reaction monitoring mode with positive ESI at m/z 532.3 → 296.1 for mirodenafil, m/z 488.1 → 296.1 for SK-3541, and m/z 517.3 → 283.2 for udenafil. The calibration curves were linear over a concentration range of 2-500 pg/mL using 0.5 mL plasma for the microdose of mirodenafil (100 μg). Analytical method validation of the clinical dose (100 mg), with a calibration curve range of 2-500 ng/mL using 0.025-mL plasma, was also conducted. The other LC-MS/MS conditions were similar to those used for the microdosing. Each method was applied successfully to pharmacokinetic studies after a microdose or clinical dose of mirodenafil to six healthy Korean male volunteers.

[1]  J. Y. Lee,et al.  Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study. , 2007, Journal of pharmaceutical and biomedical analysis.

[2]  Yuichi Sugiyama,et al.  Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  Toshihiko Ikeda,et al.  Cost-effectiveness analysis of microdose clinical trials in drug development. , 2013, Drug metabolism and pharmacokinetics.

[4]  I. Jang,et al.  Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  Changsun Choi,et al.  The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, mirodenafil (SK3530), in rabbits with acute spinal cord injury. , 2008, The Journal of veterinary medical science.

[6]  Jon L Ruckle,et al.  Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. , 2008, Journal of pharmaceutical sciences.

[7]  J. Shon,et al.  Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials , 2011, Archives of pharmacal research.

[8]  Oliver Langer,et al.  Microdosing Studies in Humans , 2008 .

[9]  Kazuya Maeda,et al.  Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose , 2011, Pharmacogenetics and genomics.

[10]  Y Kumagai,et al.  Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing Study , 2011, Clinical pharmacology and therapeutics.

[11]  R. C. Garner,et al.  Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data. , 2010, Bioanalysis.

[12]  Y Kumagai,et al.  Microdose study of a P‐glycoprotein substrate, fexofenadine, using a non‐radioisotope‐labelled drug and LC/MS/MS , 2010, Journal of clinical pharmacy and therapeutics.

[13]  Graham Lappin,et al.  The phase 0 microdosing concept. , 2006, British journal of clinical pharmacology.

[14]  R. C. Garner,et al.  The use of accelerator mass spectrometry to obtain early human ADME/PK data , 2005, Expert opinion on drug metabolism & toxicology.

[15]  Kwangsung Park,et al.  Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. , 2008, The journal of sexual medicine.

[16]  Kazuya Maeda,et al.  Novel strategies for microdose studies using non-radiolabeled compounds. , 2011, Advanced drug delivery reviews.

[17]  H. Ouyang,et al.  Microdosing Assessment to Evaluate Pharmacokinetics and Drug Metabolism in Rats Using Liquid Chromatography-Tandem Mass Spectrometry , 2008, Pharmaceutical Research.

[18]  J. Kim,et al.  The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. , 2009, Clinical therapeutics.

[19]  B. Matuszewski,et al.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. , 2003, Analytical chemistry.

[20]  Shinobu Kudoh,et al.  A highly sensitive LC-MS/MS method capable of simultaneously quantitating celiprolol and atenolol in human plasma for a cassette cold-microdosing study. , 2011, Journal of separation science.

[21]  H. Rosing,et al.  Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not? , 2005, Rapid communications in mass spectrometry : RCM.